Aptose Biosciences Inc. ((APTOF)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Aptose Biosciences Inc. is conducting a clinical study titled ‘A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)’. The study aims to identify a safe and potentially effective dose of tuspetinib for patients with relapsed or refractory AML, myelodysplastic syndromes with increased blasts grade 2 (MDS-IB2), or chronic myelomonocytic leukemia (CMML), as well as newly diagnosed AML.
The intervention being tested is tuspetinib, administered alone or in combination with other drugs such as venetoclax and azacitidine. Tuspetinib is intended to treat patients by targeting specific pathways involved in leukemia cell survival and proliferation.
The study follows a non-randomized, sequential intervention model with no masking, focusing primarily on treatment. It includes several parts: dose escalation, dose exploration, and dose expansion phases, both as a monotherapy and in combination with other drugs.
The study began on January 28, 2019, and the latest update was submitted on August 20, 2025. These dates are crucial for tracking the progress and timelines of the study, which is currently recruiting participants.
This study update could potentially impact Aptose Biosciences’ stock performance positively, as successful results may enhance investor confidence and market position, especially in the competitive field of leukemia treatment. Investors should monitor the progress closely as it may influence market dynamics.
The study is ongoing, and further details are available on the ClinicalTrials portal.